Crinetics Pharmaceuticals, Inc.
CRNXCrinetics Pharmaceuticals, Inc. (CRNX) is a biotechnology company focused on developing novel therapeutics for rare endocrine disorders and other hormonal conditions. Founded with an emphasis on hormones that regulate essential physiological processes, Crinetics designs small molecule drugs targeting specific receptor pathways to address unmet medical needs. The company's pipeline includes treatments for conditions such as acromegaly, carcinoid syndrome, and hypogonadism.
Company News
Investor rights law firm Halper Sadeh LLC is investigating Element Solutions Inc, Crinetics Pharmaceuticals Inc, and Solstice Advanced Materials Inc for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether insiders are receiving preferential benefits...
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its cystic fibrosis focus into endocrine disease treatments. The deal could add up to $5 billion in annual revenue through approved drug Palsonify and pipeline candidate Atumelnant. While Vertex's stock initially fell post-announcement, the au...
Crinetics Pharmaceuticals stock surged 98% this week following Vertex Pharmaceuticals' announcement of a $10 billion acquisition deal. Crinetics, which recently had its first FDA-approved drug (Palsonify) for acromegaly treatment, is now trading just below the $85 per share acquisition price. The deal allows Vertex to diversify beyond its cystic ...
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the...
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholders' inte...
